⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723676 | 0.93 | — | — | |
| SCHEMBL391423 | 0.93 | — | — | |
| SCHEMBL21356989 | 0.90 | CA1 (1.00) | — | |
| Hydrochloric Acid SCHEMBL29819829 | 0.90 | CA1 (0.88) | — | |
| SCHEMBL2724764 | 0.90 | CA1 (1.00) | — | |
| SCHEMBL392889 | 0.90 | CA1 (1.00) | — | |
| SCHEMBL2017488 | 0.90 | CA1 (1.00) | — | |
| SCHEMBL11688163 | 0.85 | CA1 (0.69) | — | |
| SCHEMBL4141702 | 0.85 | — | — | |
| SCHEMBL20231524 | 0.82 | CA1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117769413-A | Combination of LSD1 inhibitors for the treatment of medullary carcinoma | 奥莱松基因组股份有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-109251588-B | Inorganic nano material ink, preparation method and application thereof, and QLED device | TCL科技集团股份有限公司 | 2021-06-22 | — | — | CN | claimed |
| EP-3255043-B1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2021-01-20 | — | — | EP | claimed |
| CN-109152780-A | CXCR-2 inhibitors for the treatment of crystalline joint disorders | 阿迪亚生命科学公司 | 2019-01-04 | — | — | CN | claimed |
| CN-106170294-A | Antibacterial combinations containing polymyxins | 斯佩罗旋转酶公司 | 2016-11-30 | — | — | CN | claimed |
| US-20160108023-A1 | Novel Compound | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | US | claimed |
| US-9221782-B2 | Compound | ASTRAZENECA AB (SE) | 2015-12-29 | — | — | US | claimed |
| US-20140228339-A1 | Novel Compound | ASTRAZENECA AB (SE) | 2014-08-14 | — | — | US | claimed |
| EP-2731945-A1 | N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | AstraZeneca AB (SE) | 2014-05-21 | — | — | EP | claimed |
| US-20130040926-A1 | NOVEL COMPOUND | ASTRAZENECA UK LIMITED | 2013-02-14 | — | — | US | claimed |
| WO-2013008002-A1 | N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2013-01-17 | — | — | WO | claimed |
| JP-4795352-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | claimed |
| CN-101528748-A | Imidazopyridazines as PI3K lipid kinase inhibitors | NOVARTIS AG (CH) | 2009-09-09 | — | — | CN | claimed |
| EP-1809624-A1 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-07-25 | — | — | EP | claimed |
| EP-1188755-B1 | ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-05-03 | — | — | EP | claimed |
| WO-2006024823-A1 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | claimed |
| WO-2005019191-A2 | 1, 1-DIOXIDO-4H-1,2,4-BENZOTHIADIAZINE DERIVATE UND VERWANDTE VERBINDUNGEN ALS INHIBITOREN DER HCV POLYMERASE ZUR BEHANDLUNG VON HEPATITIS C | ABBOTT LABORATORIES (US) | 2005-03-03 | — | — | WO | claimed |